Industry
Biotechnology
Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. The company's pipeline includes extended half-life antibodies targeting a4ß7, TL1A, and IL-23. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was founded in 2013 and is based in Waltham, Massachusetts.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
March 18, 2024 | 5:11 pm
Portfolio Pulse from Benzinga Newsdesk
March 18, 2024 | 12:02 pm
Portfolio Pulse from Avi Kapoor
March 05, 2024 | 3:56 pm
Portfolio Pulse from Benzinga Newsdesk
March 01, 2024 | 5:30 pm
Portfolio Pulse from Benzinga Newsdesk
March 01, 2024 | 4:10 pm
Portfolio Pulse from Happy Mohamed
February 29, 2024 | 9:32 pm
Portfolio Pulse from Benzinga Newsdesk
February 08, 2024 | 12:34 pm
Portfolio Pulse from Benzinga Newsdesk
December 20, 2023 | 1:46 pm
Portfolio Pulse from Benzinga Newsdesk
December 18, 2023 | 3:50 pm
Portfolio Pulse from Benzinga Newsdesk
December 11, 2023 | 8:33 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.